Accurate detection of subclonal single nucleotide variants in whole genome amplified and pooled cancer samples using HaloPlex target enrichment by Eva C Berglund et al.
Berglund et al. BMC Genomics 2013, 14:856
http://www.biomedcentral.com/1471-2164/14/856METHODOLOGY ARTICLE Open AccessAccurate detection of subclonal single nucleotide
variants in whole genome amplified and pooled
cancer samples using HaloPlex target enrichment
Eva C Berglund1*†, Carl Mårten Lindqvist1†, Shahina Hayat1, Elin Övernäs1, Niklas Henriksson1, Jessica Nordlund1,
Per Wahlberg1, Erik Forestier2,4, Gudmar Lönnerholm3,4 and Ann-Christine Syvänen1Abstract
Background: Target enrichment and resequencing is a widely used approach for identification of cancer genes and
genetic variants associated with diseases. Although cost effective compared to whole genome sequencing, analysis of
many samples constitutes a significant cost, which could be reduced by pooling samples before capture. Another
limitation to the number of cancer samples that can be analyzed is often the amount of available tumor DNA. We
evaluated the performance of whole genome amplified DNA and the power to detect subclonal somatic single
nucleotide variants in non-indexed pools of cancer samples using the HaloPlex technology for target enrichment and
next generation sequencing.
Results: We captured a set of 1528 putative somatic single nucleotide variants and germline SNPs, which were
identified by whole genome sequencing, with the HaloPlex technology and sequenced to a depth of 792–1752. We
found that the allele fractions of the analyzed variants are well preserved during whole genome amplification and that
capture specificity or variant calling is not affected. We detected a large majority of the known single nucleotide
variants present uniquely in one sample with allele fractions as low as 0.1 in non-indexed pools of up to ten samples.
We also identified and experimentally validated six novel variants in the samples included in the pools.
Conclusion: Our work demonstrates that whole genome amplified DNA can be used for target enrichment equally
well as genomic DNA and that accurate variant detection is possible in non-indexed pools of cancer samples. These
findings show that analysis of a large number of samples is feasible at low cost, even when only small amounts of DNA
is available, and thereby significantly increases the chances of indentifying recurrent mutations in cancer samples.
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Deep sequencingBackground
During the past decade, next generation sequencing
(NGS) technologies have revolutionized the field of
human genetics. Since the first draft of the human
genome was published in 2001 [1,2], a multitude of
personal genomes have been sequenced [3]. Large-scale
efforts of whole genome sequencing (WGS) of human
samples have mainly focused on population-based stu-
dies [4] and cancer genomes [5,6]. For most research* Correspondence: eva.berglund@medsci.uu.se
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reproduction in any medium, provided the orgroups, WGS of many samples remains a costly en-
deavor, and targeted capture followed by sequencing of
selected genomic regions of interest provides an attract-
ive, cost-effective alternative. Target capture of custom
designed regions and exome sequencing has allowed
identification of causal variants in several Mendelian
disorders [7], variants associated with complex diseases
[8], and recurrently mutated cancer genes [9].
Target capture technologies can be categorized into
methods based on PCR amplification, hybrid capture, or
selective circularization [10]. The HaloPlex technology is
a selective circularization-based method which is a fur-
ther development of the principle of selector probesal Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Berglund et al. BMC Genomics 2013, 14:856 Page 2 of 11
http://www.biomedcentral.com/1471-2164/14/856[11-13]. In the HaloPlex technology, genomic DNA is
fragmented by restriction enzyme digestion and circu-
larized by hybridization to probes whose ends are com-
plementary to the target fragments. Compared to hybrid
capture methods, the HaloPlex system requires smaller
amounts of starting DNA, has higher specificity (fraction
of sequence reads in the region of interest), and provides
more even genome coverage [10]. The sample pre-
paration is less laborious because incorporation of
sequencing adapters during capture obviates the need
for a separate library preparation step. However, a
maximum of 5 Mb of custom designed regions can be
enriched with current protocols, which is little compared
to for example 24 Mb for SureSelect hybrid capture.
To further decrease costs, samples can be pooled prior
to capture. Indexing of samples before pooling allows
posterior identification of the sample where a variant
occurred, and results in more accurate estimation of al-
lele frequencies. However, the presence of an additional
index tag may complicate experimental procedures,
decrease capture specificity, and result in a substantial
proportion of reads with an inappropriate index tag
[14,15]. Indexed pooling is feasible in hybrid capture
methods, where the sequencing library is prepared
before capture, but not for the current HaloPlex proto-
col, where the capture is performed on genomic DNA.
Pooling without indexing can be done at the level of
genomic DNA, and is thus an efficient approach in
terms of reagent costs and experimental work load.
While non-indexed pooling has not yet been used with
the HaloPlex technology, several studies have evaluated
the performance of non-indexed pools using hybrid
capture. These studies have yielded conflicting results,
with some observing accurate SNP calling and determin-
ation of allele frequencies [15,16], while others observe
poor allele frequency estimates or failure to validate
SNPs with minor allele frequencies below 25% [17,18].
Previous studies of non-indexed pooling aimed at
establishing methods for detecting rare variants in com-
plex phenotypes, using HapMap cell lines or other non-
tumor samples. To our knowledge, pooling of cancer
samples for identification of somatic single nucleotide
variants (SNVs) has not been evaluated to date. In con-
trast to germline SNPs, most somatic SNVs are not ex-
pected to be recurrent in the population, nor in other
individuals with the same type of cancer. Additionally,
cancer samples often consist of multiple tumor sub-
clones in mixtures with normal cells, and the proportion
of sequence reads containing an SNV can therefore be
very low in pools of cancer samples. Another consider-
ation when working with tumor samples is that DNA re-
sources are often limited. Whole genome amplification
(WGA) by multiple displacement amplification is a
standard method to increase DNA quantity. Evaluationof whole genome amplified DNA (wgaDNA) for geno-
typing purposes has shown that the allele fractions in
the original sample are retained provided that a suffi-
cient amount of genomic DNA is used [19,20]. The use
of wgaDNA in WGS can result in uneven coverage and
introduce false positive inversions [21], and in hybrid
capture it has been associated with accurate SNP detec-
tion but a slightly decreased capture specificity [22].
However, it has not been properly investigated using
NGS how well the allele fractions of somatic SNVs are
preserved during WGA.
In this study, we investigated the power to detect som-
atic SNVs in non-indexed pools of up to ten cancer sam-
ples and the effect of WGA on capture specificity and
allele fractions using HaloPlex target enrichment. We
analyzed 1528 candidate SNVs and SNPs identified by
WGS of matched cancer and normal samples from two
patients with acute lymphoblastic leukemia (ALL).
Results and discussion
Design of HaloPlex target enrichment experiment
For evaluation of the performance of whole genome
amplified DNA (wgaDNA) and non-indexed pooling in
HaloPlex target enrichment, we selected 1541 candidate
single nucleotide variants (SNVs) detected during whole
genome sequencing (WGS) of two patients with acute
lymphoblastic leukemia (ALL). Thirty of the SNVs were
previously validated as somatic by PCR and Sanger se-
quencing, and one had been shown to be a false positive.
No indels were included. The candidate SNVs selected
for evaluation of the HaloPlex target enrichment system
included 749 SNVs from patient 1 and 794 from patient
2. Two of the SNVs overlapped between the patients.
We also selected 20 germline SNPs that were heterozy-
gous in both patients. For each of these 1561 variants
(1541 candidate SNVs and 20 SNPs), we defined a target
region of 3 bp, including one base upstream and one
base downstream of each variant. In addition, we se-
lected the exons of 37 genes and five custom regions
with a size ranging from 33 to 263 bp. The total number
of target regions was 2431, and together they spanned
147 kb. The design obtained from Agilent had a total
size of 798 kb and covered 99.6% of the region of inter-
est. A total of 1528 (97.9%) of the SNVs and SNPs were
covered by the design, including 1509 candidate SNVs
(726 in patient 1 and 785 in patient 2, including the two
overlapping SNVs) and 19 of the 20 germline SNPs. The
failure to completely cover a region of interest can be at-
tributed to repeated regions in the flanking sequences,
lack of restriction fragments of appropriate size, or too
large fragments relative to the read length leading to
partial sequencing of fragments.
A total of twelve samples or pools were subjected to
target capture using the HaloPlex system (Table 1). First,
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we included genomic DNA (gDNA) from cancer and
normal samples from the two whole genome sequenced
ALL patients, here called ALL1, ALL2, Normal1, and
Normal2. Second, to evaluate the effect of whole gen-
ome amplification, we included wgaDNA from the ALL1
and ALL2 samples. Third, for evaluation of non-indexed
pooling, we prepared three pools of two, five or ten ALL
samples. Each pool contained either the ALL1 or the
ALL2 sample, and the additional samples were present
in only one pool each. The pools were prepared in repli-
cate by an independent pooling procedure.
Sequence data and allele fractions
Between 84.5% and 93.1% of the raw sequence reads
mapped to the human genome, and 42.4-73.5% of these
mapped to the target region (Table 1). The average
sequence depth ranged from 792 to 1752 in the region
covered by the HaloPlex design, and from 1008 to 2254
at the 1528 SNVs and SNPs covered by the capture
design (Table 1). Virtually all SNVs and SNPs were
covered by at least one sequence read, and 91.6-97.4% of
the variants were covered at a sequence depth of at least
30 (Table 1). To determine the accuracy of the allele
fractions in the HaloPlex sequence data we utilized the
19 heterozygous germline SNPs, which are expected to
have an allele fraction of 0.5 in individual samples from
both cancer and normal cells. The allele fractions of
these SNPs deviated from the expected 0.5 by an average
of 0.064 in the HaloPlex data, compared to 0.135 in the
WGS data, demonstrating that the increased sequencingTable 1 Samples and sequence data statistics
Sample or
poola
Average sequence depth Cum
Designb Variantsc ≥
ALL1_gDNA 1385 1940 9
Normal1_gDNA 1280 1588 9
ALL2_gDNA 1466 1791 9
Normal2_gDNA 792 1008 9
ALL1_wgaDNA 1564 1831 9
ALL2_wgaDNA 1569 1706 9
ALL1_pool2 1752 2254 9
ALL2_pool5 1502 1710 9
ALL1_pool10 1044 1445 9
ALL1_pool2_rep 1150 1614 9
ALL2_pool5_rep 1021 1503 9
ALL1_pool10_rep 1386 1837 9
a Pools are named with the whole genome sequenced ALL sample included and th
a Average sequence depth in the complete region covered by the HaloPlex design.
c Average sequence depth at the 1528 candidate SNVs and SNPs covered by the Ha
d Percentage of sequence reads that map to the human genome.
e Percentage of the sequence reads mapping to the genome that map to the regiodepth in the HaloPlex data is associated with increased
precision of allele fractions (Additional file 1: Figure S1).Somatic SNVs
Accurate identification of somatic SNVs in WGS data is
challenging. Different SNV callers often yield different
results and large numbers of false positive calls [23], and
experimental validation is often required. Target capture
and deep sequencing is a well established method for
validation of large numbers of putative SNVs detected in
WGS data [24-26]. Here, we used the HaloPlex deep-
sequencing data to classify our candidate SNVs as som-
atic or “non-validated”. At the sites where a putative
SNV was detected in the WGS data, we determined the
allele fractions in the HaloPlex data, and classified an
SNV as somatic if it had an allele fraction ≥0.1 in the
gDNA ALL sample and <0.01 in the matched normal
sample. We also required a sequence depth ≥30 in both
samples in the sequencing data from HaloPlex enrich-
ment. This resulted in 227 and 305 SNVs classified as
somatic in ALL1 and ALL2, respectively, corresponding
to approximately one third of the candidate SNVs called
from WGS data (Figure 1). As a measure of confidence,
all of the 30 previously validated somatic SNVs were
classified as somatic in the HaloPlex sequence data. The
candidate SNV that had previously been shown to be a
false positive by Sanger sequencing had no supporting
reads in the HaloPlex data.
The candidate SNVs that were not somatic displayed
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Figure 1 Allele fractions for putative single nucleotide variants (SNVs) in ALL and normal samples. The allele fractions observed in
HaloPlex sequence data for 1509 candidate SNVs in ALL and normal samples. Only data from libraries derived from genomic DNA are shown.
SNVs classified as somatic are shown in red. Candidate SNVs that follow the x = y line represent putative germline SNPs that escaped detection in
the normal sample during WGS or alignment artifacts. The cluster with allele fractions close to 0 in both ALL and normal samples represents likely
false positive SNV calls. Most of the candidate SNVs with allele fractions close to 1 in the ALL sample and around 0.5 in the normal sample in
patient 2 are located in a large region of somatic loss of heterozygosity.
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the ALL and normal samples. These SNVs could pos-
sibly be germline SNPs that escaped detection in the
normal sample in the WGS data. This hypothesis is
supported by the observation that they have significantly
lower coverage in the WGS data in the normal sample
than the validated somatic SNVs (Additional file 1:
Figure S2). We also observed significantly lower confi-
dence scores from SNV calling in WGS, as measured by
the somatic score from SomaticSniper [27], in this group
of candidate SNVs (Additional file 1: Figure S2). How-
ever, germline SNPs would be expected to have an allele
fraction close to 0.5. Analysis of mappability scores and
overlaps with segmental duplications suggests that some
of the putatively germline SNPs with deviating allele
fractions might be located in repeated regions of the
genome that had escaped our filters (data not shown).
Manual inspection of sequence alignments suggests that
other candidates in this category are false positive SNVs
caused by alignment artifacts. Second, there is a cluster
of non-validated SNVs in the lower left corner in
Figure 1. Similarly to the previous category, these candi-
date SNVs display low coverage in the normal sample in
WGS data and low somatic scores (Additional file 1:
Figure S2). This observation suggests that the failure to
detect these SNVs in the HaloPlex data is not caused by
allelic dropout during HaloPlex enrichment, but rather
by sequencing errors or alignment artifacts in combi-
nation with low coverage leading to false positive SNV
calls in the WGS data. Third, ALL2 shows a cluster of
candidate SNVs with allele fractions around 0.5 in the
normal sample and close to 1 in the ALL sample. Mostof these variants are located in a previously known large
chromosomal region of somatic loss of heterozygosity.
To further verify that our criteria for classifying a
putative SNV as somatic are valid, ten somatic SNVs
(five from each patient), with allele fractions between 0.2
and 0.8, were randomly selected for PCR and Sanger
sequencing. All ten SNVs were successfully validated as
being somatic. This result, along with the different pro-
perties of somatic and non-validated SNVs, shows that
we can accurately validate somatic SNVs using HaloPlex
enrichment and deep sequencing.
Comparison of wgaDNA and gDNA
To evaluate whether alleles were lost or allele fractions
were altered during whole genome amplification, we
compared the results from gDNA and wgaDNA in the
samples ALL1 and ALL2. The percentage of reads on
target was slightly higher for the wgaDNA samples than
for the gDNA samples, showing that whole genome
amplification does not have a negative effect on capture
specificity (Table 1). A possible explanation for the
higher specificity of wgaDNA samples would be that
genomic regions that are easier to capture with the Halo-
Plex method are preferentially amplified during the WGA
process. However, since the number of experiments is lim-
ited, the observed pattern could also be caused by random
variation. A slightly smaller number of variants had a se-
quence depth ≥1 and ≥30 in the wgaDNA samples
(Table 1). Further investigation showed that the coverage
in wgaDNA samples is more uneven, with more sites cov-
ered by a relatively low or high number of reads (Figure 2).













Figure 2 Sequence depth variation in genomic DNA (gDNA)
and whole genome amplified DNA (wgaDNA) samples. Density
plot showing the variation in HaloPlex sequence depth of 1509
candidate single nucleotide variants (SNVs) and 19 germline SNPs in
gDNA and wgaDNA samples. The sequence depth is more uneven
in the wgaDNA samples, which display relatively low or high
coverage at more sites. To increase clarity, sites with a depth > 5000
are shown at 5000 and the x-axis has been cut at 0 and 5000.
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the evenness of the coverage (Additional file 1: Figure S3),
suggesting that using more of the wgaDNA would not
have yielded more even coverage. These results indicate
that in order to achieve adequate coverage of the target re-
gions, it is important to sequence wgaDNA samples at suf-
ficient depth. The number of SNVs classified as somatic
was similar in the gDNA and wgaDNA samples (Table 2).
A total of 29 SNVs were classified as somatic in only one
of the gDNA and wgaDNA experiments using the same
sample (Table 2). Five of them can be explained by lack of
coverage in the wgaDNA sample. Manual inspection of
the sequence data at the remaining SNVs suggested that
the inconsistencies were due to alignment artifacts or alleleTable 2 Detection of single nucleotide variants and error
rates in genomic DNA and whole genome amplified DNA
Sample Somatic SNVsa Errorb
ALL1_gDNA 227 (13) 0.036
ALL1_wgaDNA 223 (9) 0.020
ALL2_gDNA 305 (5) 0.038
ALL2_wgaDNA 302 (2) 0.031
a Within parenthesis is the number of candidate SNVs that were not classified
as somatic in the corresponding gDNA or wgaDNA experiment from the same
original sample.
b Average absolute difference from 0.5 for 19 germline SNPs.fractions close to the cutoff, rather than allelic dropout
during whole genome amplification.
For analysis of how well allele fractions are preserved
during whole genome amplification, we used all can-
didate SNVs detected in the WGS data as well as the
germline SNPs, with a sequence depth ≥30 in both
gDNA and wgaDNA experiments (n = 1439 variants).
This was because allele fractions are expected to be
preserved for all variants. In addition, including all va-
riants allows investigation of the preservation of the
allele fractions across the complete range of allele frac-
tions (i.e., 0–1). Cancer samples with variants with vary-
ing allele fractions are therefore particularly well suited
to assess how well allele fractions are preserved during
whole genome amplification. The error in allele fraction
for the 19 germline SNPs was slightly smaller in
wgaDNA than in gDNA, suggesting that the uneven
coverage in wgaDNA samples does not affect the allele
fractions (Table 2). We observed a high correlation
between allele fractions obtained in data from gDNA
and wgaDNA experiments, with Pearson correlation
coefficients of 0.953 in both patients (Figure 3). The rea-
son why the two patients have the same correlation
value, although there appears to be more variation in
ALL2, is that the cluster of data points in the upper right
corner has a major effect on the correlation. To better
estimate the variation in the datasets, we also calculated
the root mean square error (RMSE). This value was
0.066 and 0.093 for ALL1 and ALL2, respectively. In
addition to demonstrating that wgaDNA provides a good
substitute for gDNA when DNA resources are limited,
our results highlight the technical reproducibility of
HaloPlex enrichment.
Allele fractions in pooled DNA samples
For evaluation of variant detection and how well allele
fractions are preserved in pools, we focused on the
somatic SNVs (n = 227 in ALL1 and n = 305 in ALL2).
These variants are likely to be unique to the whole
genome sequenced sample, and therefore an expected
allele fraction for each variant can be calculated by
dividing the allele fraction in the individual gDNA sam-
ple with the number of samples in the pool. In contrast,
germline SNPs are more likely to be present in some of
the additional samples included in the pool, which
hinders the use of these variants to determine the preci-
sion of the method. A comparison between observed
and expected allele fractions showed good correlation in
all pools (Figure 4, top panel). The allele fractions in the
pools containing ALL1 displayed higher levels of correl-
ation than the pool containing ALL2. A possible explan-
ation is that ALL1 contains clear leukemic subclones
with approximately half of the SNVs having an allele
fraction around 0.2 and the remaining having an allele


















































Figure 3 Correlation between allele fractions in genomic DNA (gDNA) and whole genome amplified DNA (wgaDNA). Correlation of the
allele fractions of candidate single nucleotide variants (SNVs) and germline SNPs determined in experiments using gDNA and wgaDNA from the
same original DNA sample. Only variants with a HaloPlex sequence depth ≥30 in both gDNA and wgaDNA are shown (n = 1439). SNVs classified
as somatic are shown in black, non-validated candidate SNVs in grey, and germline SNPs in red.
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majority of somatic SNVs in ALL2 have an allele fraction
around 0.45, and this lower variability decreases the
correlation. In ALL2_pool5 and ALL1_pool10, the ob-
served allele fractions were on average higher than the
expected. We quantified the deviation between observed
and expected allele fractions by calculating the median
ratio of x- and y-values in each plot. This ratio would be
close to 1 if the data is evenly distributed around the
x-y line, as in the case of ALL1_pool2. For ALL2_pool5
and ALL1_pool10 the ratio was around 1.2. This result
suggests that approximately 25% and 12%, respectively,
of these pools consisted of the ALL2 and ALL1 samples,
compared to the expected 20% and 10%.
When comparing the pool replicates against each
other, the correlation between observed allele fractions
was somewhat lower than the correlation between
observed and expected values in the “original” pool
(Figure 4, bottom panel). This was not unexpected, since
the variance is likely to increase in pools compared to
individual reactions due to additional experimental
factors and decreased sequencing depth per sample.
Thus, in the replicate plots we compare two high-
variance experiments, while in the observed-expected
plots the expected values are obtained from a low-
variance experiment. Despite increased variance, the
median ratio between allele fractions in the replicates
was close to 1, suggesting that pooling is reproducible
and that the skewed distributions in ALL2_pool5 and
ALL1_pool10 may be caused by inaccurate DNA quanti-
fication of the individual samples in the pools or by va-
riations from pipetting small volumes of DNA samples
during pooling.Variant detection in pooled DNA samples
Since the genome sequence was unknown for all sam-
ples in the pools, except ALL1 and ALL2, we could not
use the entire target region to estimate the accuracy of
the SNV calling. Instead we focused on the sites for
which we have genetic information about somatic SNVs
in ALL1 and ALL2. Since we used an allele fraction
cutoff of 0.1 to call a somatic SNV in the HaloPlex data,
the lowest expected allele fraction in a pool is 0.1
divided by the number of samples in the pool. To allow
for inaccuracy of the DNA quantification or pipetting,
and random variation of sequenced molecules, a somatic
SNV was considered to be detected in a pool if the allele
fraction at this site was at least half the lowest expected
value. To estimate the number of true negatives and
false positives, we reasoned that the somatic SNVs are
rare, so that somatic SNVs detected in ALL1 would not
be present in pools containing ALL2 and vice versa. This
analysis showed that the vast majority of the known
SNVs present in a single sample can be reliably detected
in the pools, with the number of false negatives ranging
from 1 to 7 and the number of false positives ranging
from 1 to 14 (Table 3). As expected, more false positives
were observed in pools of many samples, however, the
false discovery rate was below 6% for all pools (Table 3).
To investigate whether the higher observed than ex-
pected allele fractions in ALL2_pool5 and ALL1_pool10
cause an upward bias in the number of detected SNVs,
we adjusted the observed allele fractions by dividing
them by the median ratio between observed and ex-
pected values. SNV calling using the adjusted allele frac-
tions showed that only one of all the SNVs that were
detected in the original analysis remained undetected


































































































































Figure 4 Correlation between expected and observed allele fractions in pools and comparison of replicated pools. The top panel shows
the correlation between expected and observed allele fractions in the three pools, where the expected value is calculated by dividing the allele
fraction observed in the ALL1 or ALL2 genomic DNA (gDNA) sample with the number of samples in the pool. Only single nucleotide variants
(SNVs) classified as somatic in the ALL1 (n = 227) or ALL2 (n = 305) gDNA samples are shown. The bottom panel shows the correlation between
allele fractions in the replicated pools. The x- and y-axes are cut at 0.5, 0.2 and 0.1 for the pools with two, five and ten samples, respectively. SNVs
with an observed allele fraction greater than this are shown in black at the cutoff value. The MR value is the median ratio between all x- and y-
values in each plot. It represents how close the two distributions are to each other, with a value of 1 indicating similar distributions.
Table 3 Accuracy of single nucleotide variant detection in
non-indexed pools
Sample TPa TNa FPa FNa FDR (%)b Novelc
ALL1_pool2 224 304 1 3 0.4 0
ALL2_pool5 304 227 0 1 0 3
ALL1_pool10 225 296 9 2 3.8 4
ALL1_pool2_rep 224 304 1 3 0.4 0
ALL2_pool5_rep 298 222 5 7 1.7 2
ALL1_pool10_rep 223 291 14 4 5.9 4
a TP: true positives; TN: true negatives; FP: false positives; FN: false negatives.
b FDR: false discovery rate, calculated as FP/(TP + FP).
c Putative novel SNVs called in the previously uncharacterized samples
included in the pools. One of the variants called in ALL2_pool5 was not called
in the corresponding replicated pool (ALL2_pool5_rep). All other novel
variants were identical between replicates.
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ALL2 in these pools does not influence the accuracy es-
timate. A closer inspection of the SNVs that remained
undetected in pools revealed that the majority had a low
expected allele fraction and a relatively low sequence
depth (Additional file 1: Figure S4), suggesting that dee-
per sequencing would allow detection of most SNVs.
We also found that the SNVs that remained undetected
in at least one pool had a significantly lower sequence
depth in the individual ALL1 and ALL2 samples com-
pared to the remaining SNVs, suggesting that they may
be located in genomic regions that are difficult to enrich.
To investigate whether novel variants could be discov-
ered in the previously uncharacterized samples in the
pools, we performed a de novo SNV calling in the entire
region of interest (147 kb) by calculating the allele frac-
tion at all sites in this region. To filter out putatively
germline SNPs and false positive calls, we set the
Berglund et al. BMC Genomics 2013, 14:856 Page 8 of 11
http://www.biomedcentral.com/1471-2164/14/856expected allele fraction for a somatic SNV present in a
single sample in a pool to 0.5 divided by the number of
samples included in the pool and we selected only vari-
ants with an allele fraction between half and twice the
expected value. We also filtered against dbSNP and the
other experiments included in the study (see Methods
for details). After applying these filters, we identified six
high-confidence candidate somatic SNVs that were
called in both replicates of the same pool (Table 3). One
additional SNV was called in pool ALL2_pool5 but not
in the replicate of this pool (Table 3). Manual inspection
of this variant suggested that it was a false positive call
caused by alignment artifacts. We performed PCR and
Sanger sequencing of each of the samples included in
the pools where the six high-confidence SNVs were
identified. In each case, we were able to show that it was
a true variant and in which DNA sample it was present.
Pooling of DNA samples before capture thus allows ac-
curate SNV detection in many samples at low reagent
cost, but at the expense of losing the information of in
which sample novel variants are detected, unless experi-
mental validation is performed. If the variants are ex-
pected to be so rare that they occur in only one sample,
this limitation can potentially be circumvented by using
a pool design where each sample is present in two differ-
ent pools and no other sample is present in both pools
[28]. In most studies, cancer samples are compared to
matched normal controls. Non-indexed pooling could be
particularly useful for the controls, since variants present
in the normal population are not believed to be cancer
mutations, even if the presence of the variant in a
matched normal sample has not been confirmed.
Conclusions
In this work, we analyzed 1528 putative somatic SNVs
and germline SNPs with the HaloPlex target enrichment
technology and NGS to evaluate the performance of
whole genome amplified DNA and the accuracy of SNV
detection in non-indexed pools of cancer samples. We
selected the HaloPlex technology since it is a novel, fast,
and specific method suitable for targeted sequencing of
relatively small regions in many samples. We found that
the allele fractions of the analyzed variants are well pre-
served during whole genome amplification, with correl-
ation coefficients of 0.953 between gDNA and wgaDNA
samples, and that WGA does not negatively affect cap-
ture specificity or variant calling. The possibility of using
wgaDNA is particularly important in cancer research,
since the amount of available DNA is often a major limi-
tation when working with primary human cancer sam-
ples. Furthermore, we show that using a sequence depth
of 792–1752, SNVs present in a single sample with allele
fractions as low as 0.1 can be reliably detected in non-
indexed pools of up to ten samples. We also identifiedand experimentally validated six novel variants in the
samples that were included in these pools. Our results
are important, since they show that analysis of a large
number of samples, including samples where limited
amounts of DNA have previously been prohibitive, is
possible at low cost. Since analysis of many samples
significantly increases the chances of finding recurrent
cancer genes, our results have great potential to be bene-
ficial for cancer research.
Methods
Samples
Sixteen bone marrow samples collected at diagnosis
from patients with childhood acute lymphoblastic
leukemia (ALL) were analyzed in this study (Additional
file 1: Table S1). All patients were treated at Swedish
centers according to the Nordic Society for Pediatric
Haematology and Oncology (NOPHO) 1992 and 2000
ALL protocols [29]. The study was approved by the Re-
gional Ethical Review Board in Uppsala, Sweden. The
study was conducted according to the guidelines of the
Declaration of Helsinki, and all patients and/or guard-
ians provided written or oral informed consent.
We have previously performed whole genome sequen-
cing of two of the ALL samples included in the study
(ALL1 and ALL2), along with matched normal samples
from the same patients (Lindqvist et al., manuscript in
preparation). Both patients responded well to therapy,
and at examination after cessation of therapy 2-2½ years
after diagnosis they were found to be in first continuous
complete remission (CCR 1), with <0.01% blast cells in
the bone marrow according to PCR. The normal blood
samples were collected 2½-3 years later, when the pa-
tients were still in CCR 1 with normal hematological
parameters. The patients are today clinically well in CCR
1 another 2½-3 years later. Thus, there is good evidence
that the normal blood samples did not contain any
leukemic cells. The proportion of leukemic cells in the
cancer samples was estimated to be >90% by light mi-
croscopy in May-Grünwald-Giemsa-stained cytocentri-
fuge preparations.
For whole genome sequencing, on average 138 Gb
paired-end sequence data was generated for each sample
using the HiSeq2000 or GAIIx instruments (Illumina). Se-
quence reads were trimmed from the 3’ end and aligned
to the human reference genome (version hg19) using
BWA version 0.5.9 [30] with default parameters. Read re-
alignment and base quality recalibration was performed
using GATK version 1.0.5909 [31]. Read realignment
was performed around candidate indels identified dur-
ing the run and indels previously called in the data using
VarScan [32]. During base quality recalibration, dbSNP132
and the BAQ option was used. PCR duplicates and read
pairs where at least one read fulfilled any of the following
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or MAPQ <30. Somatic SNVs were predicted with MuTect
version 1.0.27200 [33] and SomaticSniper version 1.0.0 [27]
with default parameters. MuTect SNVs labeled REJECT
and SomaticSniper SNVs with somatic score <40 were
discarded. In addition, SNVs with an allele fraction <0.2,
SNVs present in dbSNP135, and SNVs overlapping a re-
peated region present in the tracks “rmsk” or “simpleRe-
peats” from the UCSC table browser were excluded from
further analysis.
Target capture and sequencing
Capture of the target regions was performed with re-
agents from a custom design HaloPlex Target Enrich-
ment kit 1-500 kb (Agilent, USA), according to the
HaloPlex Target Enrichment System-Fast Protocol Ver-
sion B. Briefly, the protocol consists of the following
four steps: 1) Digestion of genomic DNA in eight differ-
ent restriction reactions. 2) Hybridization of restricted
fragments to probes whose ends are complementary to
the target fragments. During hybridization, fragments
are circularized and sequencing motifs including index
sequences are incorporated. 3) Capture of target DNA
using streptavidin beads and ligation of circularized frag-
ments. 4) PCR amplification of captured target libraries.
Recent revisions of the protocol are listed in Additional
file 2.
Whole genome amplification was performed using
50 ng of genomic DNA with reagents from the Repli-g
midi kit (Qiagen), according to the manufacturer’s in-
structions. 200 ng of DNA was used for capture reac-
tions containing a single sample. 100 ng of DNA from
each sample was used for pooling and all pooled DNA
was used in the capture reaction. Thus, the amount of
input DNA ranged from 200–1000 ng in the capture ex-
periments. Prior to pooling, DNA was quantified using a
Qubit Fluorometer (Invitrogen). Paired-end sequencing
(100 bp reads) of all samples was performed in a single
lane on a HiSeq2000 instrument (Illumina, USA). A
HiSeq Paired End Cluster Generation Kit was used to
generate the clusters and a TruSeq SBS Kit v3 was used
for sequencing. Image analysis and base calling was per-
formed using the Illumina RTA software version 1.13.48.
Data analysis
Sequence reads were trimmed to remove Illumina
adapter sequences with CutAdapt version 1.1 [34] and
aligned to the human reference genome (version hg19)
with MOSAIK version 2.1.33 with default parameters.
Realignment and recalibration of base quality scores
using dbSNP137 was performed with GATK version
1.0.5909 [31]. Read realignment was performed around
candidate indels identified during the run, and SNPs and
indels in dbSNP137 that were located in the regionscovered by the HaloPlex design. Reads with MAPQ = 0
were discarded.
Allele fractions at sites with candidate SNVs detected
in WGS data and germline SNPs were calculated with a
custom Python script (publicly available at https://
github.com/Molmed/Berglund-Lindqvist-2013). Variant
calling was based on these allele fractions. In individual
samples, a candidate SNV was classified as somatic if
fulfilling the following criteria: allele fraction ≥0.1 in the
gDNA ALL sample, allele fraction <0.01 in the matched
normal sample, and HaloPlex sequence depth ≥30 in
both samples. In pools, we considered a validated som-
atic SNV to be detected if the allele fraction was ≥0.05
divided by the number of samples in the pool.
For de novo SNV calling in pools, we investigated the
allele fractions at every site in the 147 kb target region
that had a sequence depth ≥30 per sample included in
the pool. We only searched for variants in the unknown
(i.e., not whole genome sequenced) samples. We applied
several criteria to filter out putative germline SNPs and
false positive calls. First, we assumed that variants that
are present in more than one of the samples in a pool
are likely to be germline, and we focused on finding vari-
ants with an allele fraction suggesting that they are
present in only one sample. We set the expected allele
fraction for such variants to 0.5 divided by the number
of samples in the pool. We excluded variants with an
allele fraction less than half or more than twice the
expected value. Second, we filtered out all variants
present in dbSNP137. Third, we excluded variants that
had an allele fraction >1% in any of the other experi-
ments included in the study except the replicate experi-
ment. This was to filter out germline variants that are
not in dbSNP and putative false positive calls caused by
alignment artifacts. Validation of putative novel SNVs
was done by PCR amplification and Sanger sequencing
of each of the samples included in the pools individually.
Figures were generated using R version 3.0.1.
PCR and Sanger sequencing
PCR primers were designed using Primer3Plus [35].
PCR was performed using a Smart Taq Hot Thermo-
stable DNA Polymerase Set (Naxo, Estonia) for 35 cycles.
Sanger sequencing was performed with an ABI3730XL
instrument at the Genome Center in Uppsala, Sweden.
The sequence traces were analyzed with the Sequencher
software (Applied Biosystems).
Additional files
Additional file 1: Figure S1. The allele fractions and sequencing depths
of 19 heterozygous germline SNPs in HaloPlex and whole genome
sequencing data. Figure S2. Comparison of somatic and non-validated
single nucleotide variants (SNVs) in terms of sequence depth for the normal
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from SNV calling as measured by the somatic score from SomaticSniper.
Figure S3. Comparison of the evenness of coverage, as estimated by the
coefficient of variation (CV) and the Gini index, between experiments
with different amounts of input DNA. Figure S4. The sequence depth
and expected allele fraction of somatic SNVs that remained undetected
in pools. Table S1. Clinical characteristics of ALL samples used in the
study.
Additional file 2: List of revisions of the HaloPlex target capture
protocol between our experiment and the newest version of the
protocol.
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